Hydroxyapatite Vs Fluoride: What the Evidence Means for Clinical Practice
By Kristen Pratt Machado
Originally at decisionsindentistry.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Practicing dentists and hygienists must decide whether to stock, recommend, or prescribe hydroxyapatite-based products as patients increasingly ask for fluoride-free alternatives; current evidence shows comparable remineralization and sensitivity relief but leaves dosing, long-term caries outcomes, and regulatory clearance unclear.
Key points
- Nano-hydroxyapatite formulations have demonstrated in-vitro remineralization and tubule occlusion similar to 1,000–1,500 ppm fluoride dentifrices in short-term studies.
- No U.S. FDA monograph yet establishes hydroxyapatite as an anti-caries agent, so dentists prescribing fluoride-free products may lack clear legal labeling or insurance coverage.
- Clinical decisions will hinge on patient caries risk; high-risk or Medicaid populations may still require standard fluoride protocols until longer-term RCTs are published.
- Decisions in Dentistry article flags unresolved questions around optimal particle size, concentration, and combination with fluoride that will affect product selection and chair-side recommendations.
Who should care
Read the original on Decisions in Dentistry
Full reporting and any paywall content live on decisionsindentistry.com. We summarize and score; we do not republish.
Related
- ·Regulatory
Pennsylvania Bill Would Hold Dental Insurers to Their Word on Benefit Quotes
- ·Regulatory
Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-up
- ·Regulatory
EPA releases fluoride toxicity assessment protocol: 7 notes
- ·Regulatory
Pennsylvania bill would make dental insurers pay when benefit quotes are wrong